Literature DB >> 19515965

Selective activation of the SK1 subtype of human small-conductance Ca2+-activated K+ channels by 4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 293 in the S5 segment.

Charlotte Hougaard1, Marianne L Jensen, Tim J Dale, David D Miller, David J Davies, Birgitte L Eriksen, Dorte Strøbaek, Derek J Trezise, Palle Christophersen.   

Abstract

A new small molecule, 4-(2-methoxy-phenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X), is presented as an activator of small-conductance Ca(2+)-activated K(+) (SK, K(Ca)2) channels and distinguished from previously published positive modulators of SK channels, such as 1-ethyl-2-benzimidazolinone (1-EBIO) and cyclohexyl-[2-(3,5-dimethylpyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine (CyPPA), in several aspects. GW542573X is the first SK1-selective compound described: an EC(50) value of 8.2 +/- 0.8 microM (n = 6, [Ca(2+)](i) = 200 nM) was obtained from inside-out patches excised from hSK1-expressing HEK293 cells. Whole-cell experiments showed that hSK2 and hSK3 channels were more than 10 times, and hIK channels even more than 100 times, less sensitive to GW542573X. The Ca(2+)-response curve of hSK1 was left-shifted from an EC(50)(Ca(2+)) value of 410 +/- 20 nM (n = 9) to 240 +/- 10 nM (n = 5) in the presence of 10 microM GW542573X. In addition to this positive modulation, GW542573X activated SK1 in the absence of Ca(2+) and furthermore induced a 15% increase in the maximal current at saturating Ca(2+). Thus, GW542573X also acts as a genuine opener of the hSK1 channels, a mechanism of action (MOA) not previously obtained with SK channels. The differential potency on hSK1 and hSK3 enabled a chimera approach to elucidate site(s) important for this new MOA and selectivity property. A single amino acid (Ser293) located in S5 of hSK1 was essential, and substituting the corresponding Leu476 in hSK3 with serine conferred hSK1-like potency (EC(50) = 9.3 +/- 1.4 microM, n = 5). GW542573X may activate SK channels via interaction with "deep-pore" gating structures at the inner pore vestibule or the selectivity filter in contrast to 1-EBIO and CyPPA that exert positive modulation via the intracellular calmodulin binding domain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515965     DOI: 10.1124/mol.109.056663

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.

Authors:  F Woodward Hopf; Jeffrey A Simms; Shao-Ju Chang; Taban Seif; Selena E Bartlett; Antonello Bonci
Journal:  Biol Psychiatry       Date:  2010-12-31       Impact factor: 13.382

Review 2.  Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).

Authors:  Palle Christophersen; Heike Wulff
Journal:  Channels (Austin)       Date:  2015-07-28       Impact factor: 2.581

Review 3.  The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.

Authors:  Jenny Lam; Nichole Coleman; April Lourdes A Garing; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

4.  New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.

Authors:  Nichole Coleman; Brandon M Brown; Aida Oliván-Viguera; Vikrant Singh; Marilyn M Olmstead; Marta Sofia Valero; Ralf Köhler; Heike Wulff
Journal:  Mol Pharmacol       Date:  2014-06-23       Impact factor: 4.436

5.  Immunofluorescence-based assay to identify modulators of the number of plasma membrane KCa3.1 channels.

Authors:  Corina M Balut; Yajuan Gao; Cliff Luke; Daniel C Devor
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

6.  SK channel enhancers attenuate Ca2+-dependent arrhythmia in hypertrophic hearts by regulating mito-ROS-dependent oxidation and activity of RyR.

Authors:  Tae Yun Kim; Radmila Terentyeva; Karim H F Roder; Weiyan Li; Man Liu; Ian Greener; Shanna Hamilton; Iuliia Polina; Kevin R Murphy; Richard T Clements; Samuel C Dudley; Gideon Koren; Bum-Rak Choi; Dmitry Terentyev
Journal:  Cardiovasc Res       Date:  2017-03-01       Impact factor: 10.787

7.  Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.

Authors:  David Paul Jenkins; Weifeng Yu; Brandon M Brown; Lars Damgaard Løjkner; Heike Wulff
Journal:  Assay Drug Dev Technol       Date:  2013 Nov-Dec       Impact factor: 1.738

8.  Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels.

Authors:  David Paul Jenkins; Dorte Strøbæk; Charlotte Hougaard; Marianne L Jensen; Rene Hummel; Ulrik S Sørensen; Palle Christophersen; Heike Wulff
Journal:  Mol Pharmacol       Date:  2011-03-01       Impact factor: 4.436

Review 9.  Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?

Authors:  Corina M Balut; Kirk L Hamilton; Daniel C Devor
Journal:  ChemMedChem       Date:  2012-08-07       Impact factor: 3.466

10.  Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2.

Authors:  Adebimpe W Kasumu; Charlotte Hougaard; Frederik Rode; Thomas A Jacobsen; Jean Marc Sabatier; Birgitte L Eriksen; Dorte Strøbæk; Xia Liang; Polina Egorova; Dasha Vorontsova; Palle Christophersen; Lars Christian B Rønn; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2012-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.